Trademark Strategy for Life Sciences Startups: Building and Protecting Your Commercial Identity

In the life sciences industry, patents receive the lion’s share of attention in IP strategy discussions — and for good reason, given their central role in protecting core innovations and driving commercial value. Trademarks, however, occupy an equally important and sometimes underappreciated place in the IP portfolio of a life sciences startup, and the consequences of neglecting trademark strategy in the early stages of a company’s development can be significant and long-lasting.

A trademark is a word, name, symbol, logo, color, sound, or combination of these elements that identifies and distinguishes a company’s goods or services from those of others. In the life sciences context, trademarks protect two distinct but related categories of commercial identity: the company brand itself — the name and visual identity under which the startup operates and raises capital — and, for companies that advance products to commercialization, the product brand — the proprietary name under which a drug, device, or diagnostic is marketed to healthcare providers and patients. Both of these categories present their own strategic considerations, clearance and prosecution challenges, and ongoing management obligations, and it is critical to thoughtfully address both from an early stage to build a commercially resilient and investor-ready life sciences company.

The Company Brand: Choosing and Protecting Your Name

The first trademark decision a life sciences startup makes, often without recognizing it as a trademark decision at all, is the choice of a company name. Founders frequently select a company name based on its scientific resonance, its memorability, or its availability as a domain name, without conducting an analytical clearance search that would indicate whether the name is legally available for use and registration as a trademark – but foregoing trademark clearance can be a consequential oversight.

A company that builds its identity, its investor relationships, and its scientific reputation under a name that is later refused by the trademark office(s) and/or found to infringe a pre-existing trademark may be forced to rebrand — an enormously disruptive and expensive process that can damage relationships, delay fundraising, and create confusion in the market at exactly the moment when the company is trying to establish itself.

Before committing to a company name, a startup should work with knowledgeable trademark counsel to conduct a comprehensive clearance search that examines not only registered trademarks in the relevant classes, but also common-law uses of similar names, domain registrations, and business trade name filings that might create obstacles to use or registration. The search should cover all jurisdictions in which the company expects to operate or raise capital, such as the United States, Europe, and other key markets if international activities are anticipated from the outset.

Pharmaceutical Product Naming: A Uniquely Complex Challenge

For life sciences startups that advance products through clinical development toward commercialization, the selection and protection of a proprietary product name – the brand name under which a drug or biologic will be marketed – is one of the most complex and multifaceted trademark challenges in any industry.

Unlike consumer product naming, pharmaceutical brand naming is subject to a layer of regulatory oversight that has no equivalent in other sectors. In the United States, proposed proprietary names for prescription drug products must be reviewed and approved by the U.S. Food and Drug Administration (FDA) as part of the drug approval process, and the FDA applies rigorous criteria to evaluate whether a proposed name creates an unacceptable risk of medication errors — either because it is too similar visually or phonetically to the name of another approved product, or because it is misleading about the drug’s ingredients, dosage form, route of administration, or therapeutic indication. The FDA’s review of a proposed proprietary name is conducted separately from the trademark clearance process, and a name that clears trademark examination may nonetheless be rejected by the FDA on medication safety grounds or vice versa. This means that the product naming process must integrate trademark counsel and regulatory counsel from the outset, and that multiple candidate names should be developed and evaluated in parallel to ensure that at least one survives both sets of scrutiny.

Trademark Registration: Why It Matters and How It Works

Once a company name has been cleared and selected, registering it as a trademark provides a set of legal benefits that go significantly beyond the protection available through common-law use alone.

In the United States, a federal trademark registration with the United States Patent and Trademark Office (USPTO) provides nationwide constructive notice of the registrant’s claim to the mark, a legal presumption of ownership and exclusive right to use the mark in connection with the registered goods and services, the ability to use the ® symbol, and access to federal court jurisdiction for infringement claims. Registration also creates a public record that will appear in trademark searches conducted by others, deterring subsequent adopters of confusingly similar marks.

The USPTO registration process begins with the filing of an application identifying the mark, the goods and/or services with which it will be used, and the basis for filing – either actual use in commerce or a “bona fide intent to use” the mark in commerce.

The application is examined by a USPTO trademark examining attorney, who may raise technical objections and/or substantive objections based on likelihood of confusion with prior registered marks and/or on descriptiveness grounds. Once any objections are overcome (or if none are raised), the application is published for opposition, giving third parties a 30-day opportunity to challenge the registration before it is granted.

For “intent to use” applications covering trademarks not yet used in U.S. interstate commerce — which are prevalent in the life sciences industry, given the extensive time that can pass between the selection of a mark and its eventual use — the mark cannot register until acceptable proof of use is filed. For pharmaceutical trademarks, this typically takes the form of a Statement of Use indicating use of the mark on the product as shipped across U.S. state lines for clinical trials or other testing purposes. The USPTO has stringent requirements for proof of use in U.S. interstate commerce, creating another hurdle for which consultation with trademark counsel can be a significant benefit for life sciences companies.

The entire trademark registration process, from filing to registration, typically takes one to two years in the absence of significant objections or oppositions, and the resulting registration must be maintained through periodic filings and continued use of the mark in commerce.

FDA Proprietary Name Review and USAN Designation

The regulatory dimensions of pharmaceutical product naming extend beyond the FDA’s proprietary name review to include the designation of a nonproprietary name — the generic name by which the drug will be known scientifically, and which will appear on all labeling alongside the proprietary brand name.

In the United States, nonproprietary names for drug substances are established through a process administered by the United States Adopted Names Council (USAN), which works in coordination with the World Health Organization’s International Nonproprietary Name program to assign names that are scientifically informative, globally consistent, and free of trademark conflicts. A startup developing a novel drug substance should initiate the USAN application process well in advance of anticipated approval (ideally during Phase II clinical development), because the USAN designation process takes time and because the assigned name will affect how the product is described in scientific literature, regulatory submissions, and clinical practice.

The relationship between the USAN nonproprietary name and the proprietary brand name must also be managed carefully from a trademark perspective — brand names that are too similar to the nonproprietary name, or that incorporate elements of the nonproprietary name in ways that could cause confusion, may be rejected by the FDA or may create trademark vulnerabilities over time. Although a company will not claim trademark rights in its nonproprietary name, it is still advisable to conduct at least a preliminary or “screening” trademark search to confirm that a proposed name does not inadvertently infringe on any prior trademarks.

International Trademark Strategy: The Madrid System and Beyond

Just as patents require international filing strategies to provide protection in multiple markets, trademarks must be registered in each jurisdiction where protection is sought — trademark rights are territorial in nature, and so a U.S. registration provides no protection in Europe, Asia, or Latin America. For life sciences companies operating across multiple markets, building an international trademark portfolio requires both a clear prioritization of key territories and an understanding of the filing mechanisms available to pursue protection efficiently.

The most important of these mechanisms is the Madrid System, administered by the World Intellectual Property Office (WIPO), which allows trademark owners to file a single international application designating multiple member countries — currently over 130 — and to manage the resulting registrations through a centralized process. The Madrid System significantly reduces the administrative burden and cost of international trademark filing compared to filing individually in each country, and it is the preferred approach for most life sciences companies building a global brand.

However, the Madrid System has limitations that are worth understanding — in particular, a Madrid registration is dependent on the home country application/registration for the first five years, meaning that if the home country registration is cancelled or limited during that period, the international registration is similarly affected. In addition, local counsel must be used to file responses to any refusals issued against Madrid filings.

Working with trademark counsel to develop a filing strategy that balances the efficiency of the Madrid System against its limitations, and that supplements Madrid filings with direct national applications where warranted, is an important part of building a robust international trademark portfolio.

Trademarks in Licensing and Transactions

As a life sciences startup grows and enters into licensing agreements, partnerships, and ultimately acquisition discussions, its trademark portfolio becomes an increasingly important element of its overall IP and commercial value.

In licensing transactions, the right to use a company’s brand name or product trademark may be licensed to partners, distributors, or sublicensees as part of a broader commercial arrangement, and the terms governing trademark use, including quality control provisions, approval rights over marketing materials, and the consequences of termination for the licensed trademark rights, must be carefully negotiated and documented. A trademark license that lacks adequate quality control provisions can result in a legal finding of “naked licensing” — a doctrine under which a trademark owner who fails to exercise adequate control over the quality of goods or services sold under its mark by a licensee may be deemed to have abandoned the mark entirely.

In acquisition transactions, the trademark portfolio will be subject to the same due diligence scrutiny as the patent portfolio, and acquirers will assess the strength and scope of the registrations, the history of use and enforcement, the status of international filings, and any outstanding disputes or oppositions.

A well-maintained trademark portfolio that clearly supports the commercial identity of the company’s products and that is registered in all key markets is a tangible contributor to enterprise value — and a portfolio that has been neglected, or that is encumbered by unresolved disputes or gaps in coverage, is a source of due diligence concern that can affect transaction terms. Treating trademark strategy with the same rigor and forward planning that the most sophisticated life sciences companies apply to their patent portfolios is one of the marks of a professionally managed IP program.

This article is part of our Life Sciences Startup IP Resource Center.